180 related articles for article (PubMed ID: 29315497)
21. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
22. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
23. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
24. Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016.
Shah M; Parmar A; Chan KKW
Cancer Med; 2020 May; 9(10):3407-3416. PubMed ID: 32196964
[TBL] [Abstract][Full Text] [Related]
25. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
[TBL] [Abstract][Full Text] [Related]
26. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
Vyfhuis MAL; Burrows WM; Bhooshan N; Suntharalingam M; Donahue JM; Feliciano J; Badiyan S; Nichols EM; Edelman MJ; Carr SR; Friedberg J; Henry G; Stewart S; Sachdeva A; Pickering EM; Simone CB; Feigenberg SJ; Mohindra P
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):445-452. PubMed ID: 29559292
[TBL] [Abstract][Full Text] [Related]
27. The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy.
Koshy M; Malik R; Sher DJ; Spiotto M; Mahmood U; Aydogan B; Weichselbaum RR
Clin Lung Cancer; 2014 Sep; 15(5):365-71. PubMed ID: 24984565
[TBL] [Abstract][Full Text] [Related]
28. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
29. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.
Miller ED; Fisher JL; Haglund KE; Grecula JC; Xu-Welliver M; Bertino EM; He K; Shields PG; Carbone DP; Williams TM; Otterson GA; Bazan JG
J Thorac Oncol; 2018 Mar; 13(3):426-435. PubMed ID: 29326090
[TBL] [Abstract][Full Text] [Related]
30. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.
Brower JV; Amini A; Chen S; Hullett CR; Kimple RJ; Wojcieszynski AP; Bassetti M; Witek ME; Yu M; Harari PM; Baschnagel AM
Ann Oncol; 2016 Oct; 27(10):1887-94. PubMed ID: 27502703
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.
Fenwick JD; Landau DB; Baker AT; Bates AT; Eswar C; Garcia-Alonso A; Harden SV; Illsley MC; Laurence V; Malik Z; Mayles WPM; Miles E; Mohammed N; Spicer J; Wells P; Vivekanandan S; Mullin AM; Hughes L; Farrelly L; Ngai Y; Counsell N
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):733-742. PubMed ID: 31809876
[TBL] [Abstract][Full Text] [Related]
32. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
[TBL] [Abstract][Full Text] [Related]
33. Definitive treatment patterns and survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Suzuki K; Dyer M; Truong MT; Litle V; Mak KS
Lung Cancer; 2018 Oct; 124():135-142. PubMed ID: 30268452
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non-Small Cell Lung Cancer.
Baine MJ; Sleightholm R; Neilsen BK; Oupický D; Smith LM; Verma V; Lin C
J Natl Compr Canc Netw; 2019 May; 17(5):450-458. PubMed ID: 31085762
[TBL] [Abstract][Full Text] [Related]
35. Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database.
Wen J; Liu D; Chen D; Chen J; Xu X; Chen C; Zhang F; Duan S; Zhu R; Fan M; Chen Y
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647107
[No Abstract] [Full Text] [Related]
36. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
[TBL] [Abstract][Full Text] [Related]
37. Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities.
Bilfinger T; Keresztes R; Albano D; Nemesure B
Med Sci Monit; 2016 Jul; 22():2589-94. PubMed ID: 27442604
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer.
Raman V; Jawitz OK; Yang CJ; Voigt SL; Wang H; D'Amico TA; Harpole DH; Tong BC
J Thorac Cardiovasc Surg; 2019 Dec; 158(6):1680-1692.e2. PubMed ID: 31606169
[TBL] [Abstract][Full Text] [Related]
39. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
